Bart van Lith

529 total citations
8 papers, 406 citations indexed

About

Bart van Lith is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Bart van Lith has authored 8 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 4 papers in Molecular Biology. Recurrent topics in Bart van Lith's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Bart van Lith is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Bart van Lith collaborates with scholars based in United States, Netherlands and Poland. Bart van Lith's co-authors include Allard Kaptein, Raquel Izumi, Michael Gulrajani, Todd Covey, Tjeerd Barf, Bas van de Kar, Edwin de Zwart, Fanny Krantz, Roger G. Ulrich and Paul G. Pearson and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Bart van Lith

8 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bart van Lith United States 7 319 240 131 105 87 8 406
Fanny Krantz United States 7 401 1.3× 300 1.3× 147 1.1× 129 1.2× 128 1.5× 12 495
Bas van de Kar Netherlands 8 325 1.0× 240 1.0× 129 1.0× 150 1.4× 90 1.0× 10 462
Edwin de Zwart United States 6 252 0.8× 191 0.8× 106 0.8× 104 1.0× 70 0.8× 7 356
Michael Gulrajani United States 8 542 1.7× 408 1.7× 206 1.6× 162 1.5× 159 1.8× 18 662
Arnau Montraveta Spain 12 236 0.7× 182 0.8× 119 0.9× 281 2.7× 96 1.1× 17 492
Julie Di Paolo United States 7 190 0.6× 144 0.6× 64 0.5× 78 0.7× 76 0.9× 11 266
Daisy Moreno United States 7 174 0.5× 70 0.3× 201 1.5× 178 1.7× 58 0.7× 9 430
Lesley Liu‐Bujalski United States 7 192 0.6× 104 0.4× 70 0.5× 146 1.4× 98 1.1× 10 346
Chelsey A. Raymond United States 4 289 0.9× 185 0.8× 103 0.8× 184 1.8× 123 1.4× 6 476
Meghan Rourke United States 8 370 1.2× 321 1.3× 154 1.2× 137 1.3× 132 1.5× 15 478

Countries citing papers authored by Bart van Lith

Since Specialization
Citations

This map shows the geographic impact of Bart van Lith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart van Lith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart van Lith more than expected).

Fields of papers citing papers by Bart van Lith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart van Lith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart van Lith. The network helps show where Bart van Lith may publish in the future.

Co-authorship network of co-authors of Bart van Lith

This figure shows the co-authorship network connecting the top 25 collaborators of Bart van Lith. A scholar is included among the top collaborators of Bart van Lith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart van Lith. Bart van Lith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Podoll, Terry, Paul G. Pearson, Allard Kaptein, et al.. (2022). Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 384(1). 173–186. 15 indexed citations
2.
Bruin, Gerjan de, Dennis Demont, Edwin de Zwart, et al.. (2020). Discovery of quinoline-based irreversible BTK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(14). 127261–127261. 7 indexed citations
3.
Kaptein, Allard, Terry Podoll, Gerjan de Bruin, et al.. (2019). Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity. Cancer Research. 79(13_Supplement). 2194–2194. 6 indexed citations
4.
Barf, Tjeerd, Todd Covey, Raquel Izumi, et al.. (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics. 363(2). 240–252. 272 indexed citations
5.
Harrington, Bonnie K., Heather L. Gardner, Raquel Izumi, et al.. (2016). Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS ONE. 11(7). e0159607–e0159607. 43 indexed citations
6.
Covey, Todd, Tjeerd Barf, Michael Gulrajani, et al.. (2015). Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Research. 75(15_Supplement). 2596–2596. 36 indexed citations
7.
Harrington, Bonnie K., Michael Gulrajani, Todd Covey, et al.. (2015). ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity. Blood. 126(23). 2908–2908. 17 indexed citations
8.
Gardner, Heather L., Bonnie K. Harrington, Raquel Izumi, et al.. (2014). Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. Cancer Research. 74(19_Supplement). 1744–1744. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fanny Krantz Breakdown of academic impact, for papers by Bas van de Kar Breakdown of academic impact, for papers by Edwin de Zwart Breakdown of academic impact, for papers by Michael Gulrajani Breakdown of academic impact, for papers by Arnau Montraveta Breakdown of academic impact, for papers by Julie Di Paolo Breakdown of academic impact, for papers by Daisy Moreno Breakdown of academic impact, for papers by Lesley Liu‐Bujalski Breakdown of academic impact, for papers by Chelsey A. Raymond Breakdown of academic impact, for papers by Meghan Rourke
Rankless by CCL
2026